안티트롬빈 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2025-2034년)

Growth Factors of antithrombin Market

The global antithrombin market was valued at USD 388.18 million in 2025 and is witnessing steady expansion driven by rising demand for anticoagulant therapies in both hereditary and acquired thrombotic conditions. The market is projected to grow to USD 403.34 million in 2026 and further reach USD 573.7 million by 2034, registering a CAGR of 4.50% during the forecast period. Growth remains moderate but consistent, supported by increasing surgical procedures, advancements in plasma-derived therapies, and broader clinical applications of antithrombin concentrates. Europe dominated the global market in 2025, accounting for 42.41% share, supported by strong plasma-derived medicinal product manufacturing capacity and high product approval rates.

Antithrombin is a naturally occurring glycoprotein that inhibits thrombin and other serine proteases, playing a crucial role in regulating blood coagulation. Therapeutically, antithrombin concentrates are widely used in patients with hereditary antithrombin deficiency, heparin resistance, major surgeries, and extracorporeal membrane oxygenation (ECMO), positioning the product as a critical anticoagulant therapy in complex clinical settings.

Market Drivers and Growth Factors

One of the primary drivers of market growth is the expanding clinical applications of antithrombin beyond traditional thrombotic disorders. Research continues to explore its role in preeclampsia, organ transplantation, continuous renal replacement therapy (CRRT), hemorrhagic shock, and inflammatory conditions. Additionally, the rising prevalence of hereditary antithrombin deficiency, estimated to affect 0.02%-0.2% of the general population, is driving demand for replacement therapy.

Another major growth factor is the increasing number of cardiovascular, transplant, and neonatal surgeries, where antithrombin supplementation is critical, particularly in patients exhibiting heparin resistance. The growing need for advanced anticoagulation management in surgical and intensive care settings continues to support market expansion.

Market Restraints and Challenges

Despite favorable demand, the market faces restraints due to safety concerns associated with antithrombin therapy, including bleeding risk, allergic reactions, and thromboembolic complications. These risks may limit widespread adoption, especially in less-monitored clinical environments.

High treatment costs remain a significant challenge, particularly in low- and middle-income countries. The availability of alternative anticoagulants such as heparin, direct thrombin inhibitors, and direct oral anticoagulants (DOACs) further restricts antithrombin uptake. Additionally, complex plasma-derived manufacturing processes, donor dependency, and stringent regulatory requirements contribute to supply limitations and extended approval timelines.

Market Opportunities and Trends

A key market opportunity lies in the growing adoption of antithrombin as combination therapy, particularly with heparin. Studies indicate that combined use produces a synergistic anticoagulant effect, enhancing therapeutic efficacy in high-risk patients. This trend is gaining traction in critical care and surgical settings.

One of the most notable market trends is the increasing use of antithrombin in surgical procedures, including liver transplantation and cardiac surgery, where thrombosis prevention is essential. The rising global surgical volume is reinforcing long-term demand for antithrombin concentrates.

Segmentation Analysis

By Source

By source, human plasma-derived antithrombin dominated the market, accounting for 98.2% share in 2024, supported by established efficacy and wide availability. Recombinant antithrombin products remain limited due to fewer approvals and higher development complexity.

By Application

The therapeutic segment led the market and is projected to capture 95.9% share in 2025, driven by high clinical demand for treating antithrombin deficiency and heparin resistance. The research & diagnostic segment is expected to grow at a slower pace due to limited product availability.

By Dosage Form

The lyophilized powder segment dominated with 97.7% market share in 2025, favored for stability, storage convenience, and widespread clinical use. Liquid formulations remain niche due to limited product offerings.

By End User

Hospitals & clinics accounted for the largest share in 2024, driven by inpatient treatments and surgical usage. The pharmaceutical & biotechnology segment is expected to grow steadily due to increasing research applications.

Regional Outlook

Europe led the global market, valued at USD 170.72 million in 2026, supported by extensive plasma collection infrastructure and regulatory approvals. Asia Pacific reached USD 145.99 million in 2025, driven by rising congenital deficiency cases and expanding domestic manufacturing. North America recorded USD 45.9 million in 2025, constrained by limited product availability and stringent regulations. The rest of the world showed slower growth due to restricted access to plasma-derived therapies.

Competitive Landscape

The market is led by CSL, supported by a strong plasma-derived product portfolio. Grifols, S.A. and Octapharma AG maintain significant positions through product expansion and global plasma networks. Other notable players include Takeda Pharmaceutical Company Limited and Kedrion S.p.A., all actively pursuing clinical studies, approvals, and manufacturing expansion to sustain competitiveness in the global antithrombin market.

Report Coverage

The global antithrombin market report provides a detailed and comprehensive assessment of the industry for the period 2025 to 2034, with 2025 as the base year, 2026 as the estimated year, and 2034 as the forecast year. The report evaluates market size, market value, growth trajectory, and structural developments influencing the evolution of antithrombin therapies across major regions.

The study includes in-depth segmentation analysis based on source, application, dosage form, and end user, highlighting the dominance of human plasma-derived antithrombin, therapeutic applications, lyophilized dosage forms, and hospital & clinic usage. Regional coverage spans Europe, Asia Pacific, North America, and the rest of the world, offering insights into plasma collection infrastructure, regulatory environments, product availability, and regional demand patterns.

Additionally, the report examines market drivers, restraints, opportunities, challenges, and emerging trends, including expanding clinical applications, combination therapy adoption, and increased surgical utilization. The impact of COVID-19 on demand dynamics and clinical usage is also assessed. The competitive landscape section analyzes strategic initiatives such as product development, clinical trials, regulatory approvals, and capacity expansions undertaken by leading companies including CSL, Grifols, S.A., and Octapharma AG.

Conclusion

The global antithrombin market demonstrated steady performance in 2025, reaching a market value of USD 388.18 million, supported by rising demand for anticoagulant therapies in hereditary antithrombin deficiency, heparin resistance, and complex surgical procedures. Continued expansion to USD 403.34 million in 2026 and a projected value of USD 573.7 million by 2034 reflects sustained clinical reliance on antithrombin concentrates despite the availability of alternative anticoagulants.

Market growth is driven by expanding therapeutic applications, increasing surgical volumes, and growing adoption of antithrombin in combination therapy with heparin. However, high treatment costs, safety concerns, donor dependency, and stringent regulatory frameworks continue to limit broader adoption, particularly in low- and middle-income regions.

Regionally, Europe maintains market leadership due to strong plasma-derived medicinal product manufacturing capacity and high approval rates, followed by Asia Pacific, where rising congenital deficiency cases and domestic production expansion are improving accessibility. North America and the rest of the world exhibit comparatively slower growth due to limited product availability and regulatory constraints. Overall, the antithrombin market is positioned for moderate but consistent long-term growth, supported by clinical necessity, ongoing research, and expanding use in advanced therapeutic and surgical settings.

Segmentation By Source, Application, Dosage Form, End User, and Region

By Source * Human Plasma

• Others

By Application * Therapeutic

• Research & Diagnostic

By Dosage Form * Lyophilized Powder

• Liquid

By End User * Hospitals & Clinics

• Pharmaceutical & Biotechnology Industry
• Research Institutes

By Region * North America (By Source, Application, Dosage Form, End User, and Country/Sub-Region)

• U.S.
• Canada
• Europe (By Source, Application, Dosage Form, End User, and Country/Sub-Region)
  • Germany
  • France
  • U.K.
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Source, Application, Dosage Form, End User, and Country/Sub-Region)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Southeast Asia
  • Rest of the Asia Pacific
• Rest of the World (By Source, Application, Dosage Form, and End User)

Table of Content

1. Introduction

• 1.1. Market Scope
• 1.2. Market Segmentation
• 1.3. Market Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Cardiovascular Diseases, By Key Countries
• 4.2. Regulatory Scenario, By Key Countries
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Approvals, Launches etc.)
• 4.4. Impact of COVID-19 on the Market
• 4.5. Overview: Antithrombin Market in Japan & South Korea

5. Global Antithrombin Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Source
  • 5.1.1. Human Plasma
  • 5.1.2. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Therapeutic
  • 5.2.2. Research & Diagnostic
• 5.3. Market Analysis, Insights and Forecast - By Dosage Form
  • 5.3.1. Lyophilized Powder
  • 5.3.2. Liquid
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Hospitals & Clinics
  • 5.4.2. Pharmaceutical & Biotechnology Industry
  • 5.4.3. Research Institutes
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Rest of the World

6. North America Antithrombin Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Source
  • 6.1.1. Human Plasma
  • 6.1.2. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Therapeutic
  • 6.2.2. Research & Diagnostic
• 6.3. Market Analysis, Insights and Forecast - By Dosage Form
  • 6.3.1. Lyophilized Powder
  • 6.3.2. Liquid
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Hospitals & Clinics
  • 6.4.2. Pharmaceutical & Biotechnology Industry
  • 6.4.3. Research Institutes
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Antithrombin Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Source
  • 7.1.1. Human Plasma
  • 7.1.2. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Therapeutic
  • 7.2.2. Research & Diagnostic
• 7.3. Market Analysis, Insights and Forecast - By Dosage Form
  • 7.3.1. Lyophilized Powder
  • 7.3.2. Liquid
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Hospitals & Clinics
  • 7.4.2. Pharmaceutical & Biotechnology Industry
  • 7.4.3. Research Institutes
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. Germany
  • 7.5.2. UK
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Antithrombin Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Source
  • 8.1.1. Human Plasma
  • 8.1.2. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Therapeutic
  • 8.2.2. Research & Diagnostic
• 8.3. Market Analysis, Insights and Forecast - By Dosage Form
  • 8.3.1. Lyophilized Powder
  • 8.3.2. Liquid
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Hospitals & Clinics
  • 8.4.2. Pharmaceutical & Biotechnology Industry
  • 8.4.3. Research Institutes
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. South Korea
  • 8.5.6. Southeast Asia
  • 8.5.7. Rest of Asia Pacific

9. Rest of World Antithrombin Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Source
  • 9.1.1. Human Plasma
  • 9.1.2. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Therapeutic
  • 9.2.2. Research & Diagnostic
• 9.3. Market Analysis, Insights and Forecast - By Dosage Form
  • 9.3.1. Lyophilized Powder
  • 9.3.2. Liquid
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Hospitals & Clinics
  • 9.4.2. Pharmaceutical & Biotechnology Industry
  • 9.4.3. Research Institutes

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  • 10.2.1. CSL
  • 10.2.2. Octapharma AG
  • 10.2.3. Takeda Pharmaceutical Company Limited
  • 10.2.4. Grifols, S.A.
  • 10.2.5. Medix Biochemica
  • 10.2.6. Kedrion S.p.A.
  • 10.2.7. Scripps Laboratories
  • 10.2.8. LFB